Actively Recruiting
Testing Gene PilotLX With Latinx Cancer Patients
Led by Fox Chase Cancer Center · Updated on 2025-07-03
232
Participants Needed
4
Research Sites
135 weeks
Total Duration
On this page
Sponsors
F
Fox Chase Cancer Center
Lead Sponsor
T
Temple University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a randomized controlled trial designed to evaluate the efficacy of an electronic health decision support tool called Gene PilotLX to increase informed decision making regarding hereditary risk information from tumor genomic profiling (TGP) test among Latinx cancer patients recruited at four cancer centers.
CONDITIONS
Official Title
Testing Gene PilotLX With Latinx Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Self-identified Latinx patients
- Diagnosed with solid tumor cancers
- Speak or read English or Spanish
- Able to provide informed consent
You will not qualify if you...
- Patients with hematologic or liquid cancers such as leukemia, lymphoma, or multiple myeloma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
MD Anderson Cancer Center at Cooper
Camden, New Jersey, United States, 08103
Not Yet Recruiting
2
Herbert Irving Comprehensive Cancer Center
New York, New York, United States, 10032
Not Yet Recruiting
3
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Actively Recruiting
4
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19122
Actively Recruiting
Research Team
M
Michael J Hall, MD, MS
CONTACT
S
Sarah B Bass, PhD, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here